ETHNIC DRUG
July 1st, 2004
BY KEITH NUTHALLTHE FIRST drug specifically designed for a single ethnic group is awaiting approval in the United States. The drug called BiDil was tested to treat heart failure in black patients after NitroMed, the company that sponsored the trials, argued that African Americans have a higher rate of heart failure than Americans as a whole and that they tend not to respond to some existing heart failure drugs as well as other groups. Initially, the drug failed to win approval for general use and ignited controversy when the company tested it only on black ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.